Objective: Somatoform disorders (SDs) are characterized by chronic multiple functional somatic (FS) symptoms. It has been suggested that infections may be triggers for FS symptoms to occur, pointing to the immune system as a pathogenic factor in their development. The current study aimed to compare the prevalence of infections (i.e., infection load) in the history of patients with SDs with that of matched controls. Methods: Samples (n = 185) were identified in the Psychiatric Case Register Middle Netherlands and the Julius General Practitioners Network. Patients with an SD diagnosis in the Psychiatric Case Register Middle Netherlands were compared with matched persons without somatoform complaints (controls) on their infection load in two periods before the date of the psychiatric diagnosis or a matched date for the controls (i.e., the total period for which data were available and a 3-year period). Infection load was defined as the total number of infections documented in the Julius General Practitioners Network. 
INTRODUCTION
W hen a person presents with somatic symptoms that cannot (fully) be explained by a known organic pathology, these symptoms will be labeled ''medically unexplained'' or ''functional.'' Often, more than one symptom is present, and certain constellations of symptoms give way to a diagnosis of a specific functional somatic (FS) syndrome like, for example, chronic fatigue syndrome, fibromyalgia, or irritable bowel syndrome, with specific diagnostic criteria for each syndrome (1Y3). The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) offers classifications for severe and chronic heterogeneous FS symptom presentation, such as somatoform disorder (SD) and somatization disorder (4) . With a high prevalence of FS symptoms in primary and secondary care (5, 6) , research aimed at identifying predisposing and precipitating factors in the development of FS symptoms is highly relevant (7) .
In this context, infections seem to play a role in the development of FS symptoms: infections have been indicated as a precipitating factor in the onset of FS symptoms in a subset of patients (8Y10), and a history of multiple infections (i.e., a high infection load) might predispose for the development of FS symptoms (11Y13). However, research on infections as a predisposing factor is still limited, and results are inconsistent. Two studies reported multiple infections to be risk markers for having chronic fatigue syndrome or irritable bowel syndrome (11, 12) , whereas another study did not find patients with chronic fatigue syndrome to have experienced childhood illnesses more than controls (13) . These previous studies have some limitations. First, methodological choices may have influenced the results, such as the use of subjective reports of infections or illnesses (12, 13) , or dichotomizing the occurrence of infections (e.g., none versus one or more infections) (11Y13), thereby not taking into account the potentially accumulating effect of having had several infections. Another limitation of the above-mentioned studies is the generalizability of their results, as they have focused mainly on patients with chronic fatigue syndrome and irritable bowel syndrome. Including a possibly more severe psychiatric patient group with SD (based on the DSM-IV diagnostic criteria) may provide with more sensitivity for finding effects. Thus, more research on the role for infection as a predisposing factor of FS symptoms is warranted, including other FS symptom patient groups such as patients with SD and encompassing a more elaborate and sensitive measure of infection load in the history of these patients (i.e., an objective, continuous measure of both major and minor infections).
In the current study, we estimated the infection load of patients with a DSM-IV SD diagnosis, and we compared this load with the infection load of a control group in a matched case-control design. General practitioners' (GP's) recordings of infections were collected prospectively up till the point of an SD diagnosis. We created a continuous measure of infection load, including a broad range of infections. It was hypothesized that patients with an SD would show more infections (i.e., a higher infection load) in their history than controls.
Having an SD is a significant predictor of frequent GP attendance (14, 15) . Theoretically, a high attendance frequency increases the chance for the GP to observe and record infections for which patients with a low attendance frequency would not visit their GP. Thus, one could argue that patients with an SD might have more infection registrations in a GP registry than other GP attendees, without having actually experienced more infections. In addition to reporting the number of GP contacts per group (which is expected to be larger in the somatoform group), we aimed to control for this confounder by also creating a measure of infection load including only registrations for which anti-infectious or anti-inflammatory medication was prescribed, assuming that medication would only be prescribed for more severe infections (for which low attenders would also visit their GP). Second, because psychological distress predicts high GP attendance frequency (15, 16) , we also explored the influence of psychological distress (registrations of anxiety and/or depression) as a predictor of infection load.
METHODS
For data collection, the Psychiatric Case Register Middle Netherlands (PCR-MN), a database covering all mental health care institutions in the midwestern part of the province of Utrecht, the Netherlands (17), was linked to the Julius General Practitioners Network (JGPN), a database encompassing more than 300,000 residences in the Utrecht region for the selection of the samples. The PCR-MN contains DSM classifications of patients who consult or are treated in mental health care institutions in the region. In all institutions that affiliated with the PCR-MN, patients are diagnosed by a trained psychologist or psychiatrist using standard tests (such as the structured clinical assessment for DSM-IV axis I disorders) (17) . The JGPN contains GP registrations of medical diagnoses (coded according to the International Classification of Primary Case) and medication prescriptions (coded according to the Anatomical Therapeutic Chemical Classification System).
Samples
Two samples were selected: a) persons who received a DSM-IV-TR diagnosis for an undifferentiated SD, a somatization disorder, or a pain disorder and who were accordingly treated in a psychiatric setting (SD), and b) persons in the JGPN who were not in the SD group and who did not have an FS syndrome diagnosis or a record of FS complaints (control).
SD cases were identified in the PCR-MN and were retained only if they could be identified in the JGPN, as well. Controls were obtained from the JGPN, although they could be present in the PCR-MN, as well (see the exclusion criteria below). Controls were matched to the available SD cases on sex, date of birth (T2 years), postal code (to match for social economic status), and age in the period for which data in the JGPN were available (T5 years).
General inclusion criteria were as follows: at least three consecutive years of data available in the JGPN and no registered diagnosis of a schizophrenic disorder, psychotic disorder, or bipolar disorder in the PCR-MN. Inclusion criterion for the SD group was a DSM-IV-TR diagnosis (registered in the PCR-MN) between 2005 and 2010 of undifferentiated SD, somatization disorder, or pain disorder. The criteria for exclusion in the control group were a registration in the PCR-MN of undifferentiated SD, somatization disorder, pain disorder, or conversion disorder. Furthermore, controls were excluded in case of an indication for FS symptom presence in the JGPN: a registration of irritable bowel syndrome, chronic fatigue syndrome, fibromyalgia, or hysteria/hypochondria, or at least three registrations within a period of 6 months of either of the following: tiredness or weakness, general deterioration, muscle pain, or symptoms of several or not specified muscles, not followed by a diagnosis of a medical condition within 30 days after the registration. DSM-IV and International Classification of Primary Case codes for inclusion and exclusion criteria are provided in an online supplement (Supplemental Digital Content 1, http://links.lww.com/PSYMED/A81).
Periods Over Which Registrations Were Obtained
Prospectively collected data in the JGPN were used to create the infection load measures. Relevant registrations within the JGPN were counted until the date of SD diagnosis or a matched date (T5 years) for the control group. For both the SD and control groups, registrations of infections were counted within the total period before SD diagnosis for which data were available in the JGPN. Because this period was expected to differ between cases, a year average was computed. Infection load was also assessed for a period that had the same length for all cases: the last 3 years before SD diagnosis for which data were available in the JGPN. This defines the variable ''3-year infection load.'' The choice for 3 years was based on the availability within the JGPN. Longer would have excluded too many cases, whereas a shorter period was expected to include not enough registrations to make comparisons. Note that the date of the SD diagnosis did not necessarily coincide with the end of the periods; a gap could exist between the end of a period and the date of SD diagnosis when a patient changed to a GP that was not included in the JGPN (see Fig. 1 ). On average, this gap was 11 months.
Infection Load
The ''total infection load'' was defined as the number of registrations of all infections within the JGPN. Furthermore, four subcategories of infection load were created: a) localized infections commonly without fever and with recovery within days or weeks (mild infections; e.g., acute sinusitis and viral conjunctivitis), b) localized infections commonly with fever and with recovery within days or weeks (severe infections; e.g., appendicitis and meningitis), c) systemic infections with recovery within days or weeks (e.g., influenza and measles), and d) chronic infections (e.g., chronic bronchitis and mononucleosis infectiosa).
A ''medication-treated infection load'' was also created both for the total infection load and for its subcategories in both periods. This load includes only infection and inflammatory-related registrations that were accompanied by a relevant medication prescription (e.g., antiviral, antibacterial, antiparasitic, or immune modulating). Thus, infection loads (total load and subcategories) were calculated within both time frames, including all infection registrations and including only medication-treated infection registrations.
Psychological Distress
All registered diagnoses in the JGPN of anxiety disorder or state of anxiety, depression, reactive depression, and other/not specified depression were counted as a measure of psychological distress.
GP Contacts
The number of days on which there was contact with the GP (e.g., by telephone, visit, etc) leading to a registration in the JGPN was computed as a measure of total GP contacts.
Data Analyses
All data analyses were performed with IBM SPSS statistics version 20. Because all variables showed severe skewness, which could not be improved by transformation, the Mann-Whitney U test for independent samples with Monte Carlo method for significance tests was used for group comparisons. > Value (two tailed) was set to .05 for comparisons of the total infection loads and to .01 (to account for multiple tests) for comparisons of the subcategories of infection load. For all significant tests, r (z/¾N) is reported as an indicator of effect size.
The SD group was compared with the control group on their infection load (total load and per subcategory, including all registrations and including only T
and in the 3-year period (i.e., year-average infection load). Groups were also compared on the number of GP contacts and on psychological distress. The relation between psychological distress and infection load was analyzed within both groups to test whether psychological distress might account for group differences in infection load.
RESULTS

Group Characteristics
A flowchart of the sample selection is shown in Figure 2 . One hundred ninety-five SD cases could be identified in the JGPN, of which 185 could be matched to a control. Groups did not differ in age (mean age was approximately 44 years in both groups) or sex ratio (67 % was female in both groups). The length of the total period for which information was available in the JGPN varied considerably. On average, 10.5 years of data was available, with ranges of 3.2 to 45.9 for the SD group and 3.0 to 47.1 for the control group. The groups did not differ in the length of the total period (p = .27).
In the SD group, the period between the last available date in the JGPN and the date of the somatoform diagnosis (i.e., the ''gap'' in Fig. 2) showed considerable variation. On average, JGPN data were not available for a period of 11 months preceding the diagnosis with a range of 0 to 198.80 months (mean [standard deviation] = 10.95 [7. 38] months). Thirteen percent of the SD cases had a gap of 5 years or more, and 4.9 % had a gap of 10 years or more.
As expected, SD cases had more days with GP contacts than did controls in both periods (total period: mean ranks = 227.56 versus 143.44, U = 12,614.0, z = j4.378, p G .001, r = 0.23; 3-year period: mean ranks = 209.82 versus 161.18, U = 13,291.50, z = j5.567, p G .001, r = 0.29). On average, approximately 1 in every 25 GP contacts resulted in an infection registration in the SD group and 1 in 14 in the control group, indicating that although the number of GP contacts was higher in the SD group, this seems not a probable cause for more infection registrations.
Year-Average Infection Load
The upper half of Table 1 shows the year-average total and medication-treated infection load and subcategories of infection loads.
Total Infection Load
The year-average total infection load and medication-treated infection load were significantly higher in the SD group compared with the control group (total infection load: mean ranks = 202.55 versus 168.45, r = 0.16; medication-treated infection load: mean ranks = 197.23 versus 173.77, r = 0.11).
Infection Load Per Category SD cases had a significantly higher year average of severe infections than did controls (year average: mean ranks = 201.81 versus 169.19, r = 0.16; year-average medication-treated: mean ranks = 198.08 versus 172.92, r = 0.14). Groups did not significantly differ on the other subcategories of infection load within the total period.
Three-Year Infection Load
The lower half of Table 1 shows the 3-year total and medication-treated infection load and subcategories of infection loads.
Total Infection Load
The 3-year total infection load and medication-treated infection load were significantly higher in the SD group compared with the control group (total infection load: mean ranks = 200.89 versus 170.11, r = 0.15; medication-treated infection load: mean ranks = 195.66 versus 175.34, r = 0.11). 
Infection Load Per Category
No group differences were found for any of the subcategories of infection load or medication-treated infection load within the 3-year period.
Effects of Timing on Infection Load
To get an impression of the influence of the length of the gap between available GP data within the JGPN and the psychiatric diagnosis in the PCR-MN, SD cases with a gap of 5 years or more (n = 23) and SD cases with a gap less than 5 years (n = 162) were compared on the total infection load measures. Mann-Whitney U tests showed that SD cases whose infection load was measured more closely to the date of the somatoform diagnosis had a higher infection load (all p values G.05).
Psychological Distress
The number of anxiety and depression-related registrations in the JGPN was higher in the SD group than in the control group in both periods (total period: mean ranks = 210.17 versus 160.83, U = 12,548.5, z = j6.622, p G .001, r = 0.34; 3-year period: mean ranks = 206.15 versus 164.85, U = 13,291.50, z = j5.567, p G .001, r = 0.29).
Within the control group, all associations between the number of anxiety and depression-related registrations and the total and medication-treated infection load measures were significant (year-average total infection load: Q = 0.21, p = .005; year-average medication-treated infection load: Q = 0.25, p = .001; 3-year infection load: Q = 0.20, p = .006; 3-year medication-treated infection load: Q = 0.25, p = .001). Within the SD group, however, associations were found only for the infection loads not restricted to medication-treated infections (year-average total infection load: Q = 0.18, p = .014; 3-year total infection load: Q = 0.18, p = .014).
DISCUSSION
We sought to address the question of whether a high infection load could be a predisposing factor in the development of an SD. We found that patients with an SD indeed had a higher infection load in the period preceding the psychiatric diagnosis. This was true both in the total period for which data were available and in a 3-year period that was as close to the diagnosis as possible. Our and other's (11,12) findings point to a role for the immune system in the development of FS symptoms and SD. This is in line with the immunological perspective on FS symptoms, suggesting a role for immune-brain communication (18) . On activation of the innate immune system, immune-brain communication by way of cytokines acting on the brain results in several changes in behavior and mood, together called sickness behavior (19Y21). Animal research shows that repeated immunological (or psychological) stressors can sensitize immune-brain communication, resulting in a more pronounced expression of sickness behavior in response to new (mild) stressors (22) , even in the absence of increased peripheral immunological activity (23) . Theoretically, it is possible that this sensitization of immune-brain communication caused T. E. LACOURT et al.
by multiple infections occurs in humans, as well, leading to a chronic expression of sickness behavior, that is, FS symptoms. We have shown here that patients with SDs indeed have a higher infection load than do matched controls in the time preceding their diagnosis, indicating the relevance of further research addressing immune-brain communication pathways in these and other FS patients.
Between-group comparisons of subcategories of infection load indicated that differences were mainly found in the number of acute, localized infections that are commonly accompanied by fever. Because cytokines acting on the brain are also responsible for the occurrence of fever (24) , fever during an infection would implicate immune-brain communication and thus the expression of sickness behavior. The occurrence of minor infections might not add to the infection load in patients with SD because the absence of (cytokine-induced) fever during these infections indicates a more local immunological response, possibly not affecting immune-brain pathways so much.
Patients with available GP data relatively close to the date of SD diagnosis (i.e., a small time gap) had a higher infection load than did patients with available GP data more distant from the SD diagnosis. Thus, specifically more recent infections elevate the chance for developing somatoform symptoms. This is in line with Hamilton et al. (11) , who found that recent infections (here defined as 1 year before diagnosis) posed a higher-risk factor for developing a fatigue syndrome than more distant infections (1Y3 years before diagnosis).
Beforehand, we considered the possibility that betweengroup differences in infection load could be an artifact of differences in GP attendance. As expected, we indeed found that patients with SD had more GP contact-days than did matched controls, although the question remains whether the number of GP contacts has influenced the number of infection registrations or that having more infections was the cause of more frequent GP visits. The findings in our study that patients with SD also had a higher infection load when compared with the more stringent medication-treated infection load and that psychological distress was not related to the medication-treated infection load in the SD patient group support the conclusion that the group differences found in infection load are a genuine effect. No convincing evidence was found for GP attendance to underlie a higher infection load in patients with SD.
Some limitations of the study need mentioning. First, despite having access to large registry databases for creating our two groups, the final samples were not as large as hoped for. Together with the need for nonparametric tests, which have less power than their parametric equivalents, it is possible that we lacked power to detect smaller differences. This is a limitation specifically for the interpretation of probable more subtle group differences in the subcategories of infection load. Second, our study solely included patients with SD who received their diagnosis at a mental health care institution. This is a specific sample of patients who decided to seek (or accept) psychological or psychiatric help for their symptoms, possibly indicating that this sample experienced more severe and/or heterogeneous FS symptoms and higher levels of psychological distress compared with patients who did not seek psychiatric help. It may be argued that including an SD patient group results in larger effects for the expected group differences, which is especially an advantage because our sample was smaller than expected. A disadvantage is that we cannot generalize our findings to other FS symptom patient groups. Therefore, a meaningful next step would be a replication of our results in other FS symptom patient samples. Last, because only GP registrations were used, it is possible that some specific infections were not accounted for in our measure of infection load. For example, oral infections are more commonly detected by a dentist, and they are thus underrepresented in our measure of infection load.
In conclusion, we found a higher number of infection registrations in patients with SD compared with matched controls, mainly driven by differences in severe acute local infections. We found no evidence for GP attendance to underlie these differences. It is therefore concluded that patients with an SD indeed have a higher infection load preceding their diagnosis. These findings point to a role for immune-brain communication in FS symptom development.
